共 50 条
Utilization of the microbiome in personalized medicine
被引:37
|作者:
Ratiner, Karina
[1
]
Ciocan, Dragos
[1
]
Abdeen, Suhaib K.
[1
]
Elinav, Eran
[1
,2
]
机构:
[1] Weizmann Inst Sci, Syst Immunol Dept, Rehovot, Israel
[2] DKFZ, Div Canc Microbiome Res, Heidelberg, Germany
基金:
欧洲研究理事会;
关键词:
INTERNATIONAL SCIENTIFIC ASSOCIATION;
FATTY LIVER-DISEASE;
GUT MICROBIOTA;
DIETARY FIBER;
FAECALIBACTERIUM-PRAUSNITZII;
FUSOBACTERIUM-NUCLEATUM;
CONSENSUS STATEMENT;
OBETICHOLIC ACID;
CONTROLLED-TRIAL;
GLYCEMIC INDEX;
D O I:
10.1038/s41579-023-00998-9
中图分类号:
Q93 [微生物学];
学科分类号:
071005 ;
100705 ;
摘要:
Inter-individual human variability, driven by various genetic and environmental factors, complicates the ability to develop effective population-based early disease detection, treatment and prognostic assessment. The microbiome, consisting of diverse microorganism communities including viruses, bacteria, fungi and eukaryotes colonizing human body surfaces, has recently been identified as a contributor to inter-individual variation, through its person-specific signatures. As such, the microbiome may modulate disease manifestations, even among individuals with similar genetic disease susceptibility risks. Information stored within microbiomes may therefore enable early detection and prognostic assessment of disease in at-risk populations, whereas microbiome modulation may constitute an effective and safe treatment tailored to the individual. In this Review, we explore recent advances in the application of microbiome data in precision medicine across a growing number of human diseases. We also discuss the challenges, limitations and prospects of analysing microbiome data for personalized patient care. In this study, Ratiner et al. examine the advantages, challenges and future perspectives of utilizing microbiome data in personalized medicine for optimal patient care.
引用
收藏
页码:291 / 308
页数:18
相关论文